InvestorsHub Logo
Followers 85
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: vanessapu post# 146232

Friday, 10/25/2013 10:59:56 AM

Friday, October 25, 2013 10:59:56 AM

Post# of 346182
Continued upward movement on the acceptance and fact that without ps targeting combination.....then there is no "immunotherapy".

...and a loan ....those two combined is all a BP needs to see in order to realize they have F'd up if they dont partner on Peregrine terms


"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News